<DOC>
	<DOCNO>NCT03030274</DOCNO>
	<brief_summary>This study aim investigate safety efficacy Occlutech® AFR device patient HFrEF ( Heart failure reduce ejection fraction ) HFpEF ( Heart failure preserve ejection fraction )</brief_summary>
	<brief_title>Study Assess Safety Efficacy Novel Atrial Flow Regulator ( AFR ) Heart Failure Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Age ≥18 year 2 . NYHA ( New York Heart Association ) class III IV 3 . Ongoing management heart failure accord ESC ( European Society Cardiology ) guideline previous ≥6 month 4 . Symptomatic heart failure result least one hospitalization past 12 month 5 . Absence significant ( moderate ) valvular disease ( AS ( Aortic stenosis ) , MS ( Mitral valve stenosis ) , MR ) 6 . Control arrhythmia heart rate &lt; 90bpm 7 . Life expectancy least 1 year 8 . The patient his/her legal representative ability fluently speak understand language study conduct 9 . Written , inform consent patient participation study agreement comply followup schedule 10 . Patient successful Balloon Atrial Septostomy ( BAS ) procedure stable hemodynamic state , assess investigator Echo data : 11 . LVEF ( Left ventricular ejection fraction ) ≤ 55 % 12 . Elevated leave ventricular filling pressure document Either Pulmonary capillary wedge pressure ( PCWP ) leave ventricular enddiastolic pressure rest ≥15 mmHg great central venous pressure ( CVP ) Or : Endexpiratory PCWP ≥25 mmHg exercise CVP &lt; 20 mm Hg 13 . Transseptal catheterization femoral vein access determine feasible 14 . Local generalized sepsis acute infection ( ) 15 . Any coagulation disorder , clinically relevant opinion operator . 16 . Known Allergy nickel and/or titanium and/or nickel/titaniumbased material , medically manageable . 17 . Allergy antiplatelet , coagulant , thrombotic therapy , medically manageable 18 . Intolerance contrast agent , medically manageable 19 . Participation another medical trial test therapy le 30 day intend AFR implantation procedure 20 . Transoesophageal echocardiography / use general anaesthetic contraindicate 21 . Breast feeding woman 22 . Pregnancy ( assessed patient child bear potential urine dip stick ) 23 . Occluded inferior vena cava access 24 . History ASD ( Atrial septal defect ) and/or atrial septal repair closure device place 25 . Intracardiac thrombus 26 . Patients unstable intractable angina pectoris 27 . Evidence right heart failure define ( ECHO ) Severe Right Ventricular Dysfunction ( Tricuspid annular plane systolic excursion ( TAPSE ) &lt; 14 mm ) Severe Right Ventricular Dilatation ( Right ventrical ( RV ) volume ≥ leave ventrical ( LV ) volume ) Severe pulmonary hypertension ( pulmonary arterial systolic pressure ( PASP ) &gt; 70 mm Hg ) 28 . Active malignancy 29 . Severe valve disease , implanted mechanical valve prosthesis 30 . Congenital heart defect 31 . Large Patent Foramen Ovale ( PFO ) significant atrial septal aneurysm 32 . Resting heart rate &gt; 110 bpm 33 . Inability perform 6minutes walk test 34 . Clinically relevant thrombocytopenia , thrombocytosis , leukopenia , anemia 35 . Symptomatic carotid artery disease 36 . Mitral valve stenosis 37 . Has condition , opinion Investigator , might interfere implantation , might affect patient wellbeing thereafter might interfere conduct study 38 . Systolic blood pressure &gt; 170 mmHg 24 hour ambulatory blood pressure monitoring ( ABPM ) , despite medical therapy 39 . Severe lung disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>